Back to search

Article

FDA-Approved Drug Screening in Patient-Derived Organoids Demonstrates Potential of Drug Repurposing for Rare Cystic Fibrosis Genotypes

2022-09-03

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Preclinical cell-based assays that recapitulate human disease play an important role in drug repurposing. We previously developed a functional forskolin induced swelling (FIS) assay using patient-derived intestinal organoids (PDIOs), allowing functional characterization of CFTR, the gene mutated in people with cystic fibrosis (pwCF). CFTR function-increasing pharmacotherapie...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ae82ad15-23a9-5bc7-9ce8-37d27e1b340f
DOI
10.1101/2022.09.02.506304
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
FDA-Approved Drug Screening in Patient-Derived Organoids Demonstrates Potential of Drug Repurposing for Rare Cystic Fibrosis GenotypesDOI 10.1101/2022.09.02.506304
Select a neighboring publication to make it the new centre.